Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses-Reference-Cited by-同舟云学术

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses

Published:2021-11 Issue: Volume: Page:
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Thiruvengadam Ramachandran,Awasthi Amit,Medigeshi Guruprasad,Bhattacharya Sankar,Mani Shailendra,Sivasubbu Sridhar,Shrivastava Tripti,Samal Sweety,Rathna Murugesan Deepika,Koundinya Desiraju Bapu,Kshetrapal Pallavi,Pandey Rajesh,Scaria Vinod,Kumar Malik Praveen,Taneja Juhi,Binayke Akshay,Vohra Tarini,Zaheer Aymaan,Rathore Deepak,Ahmad Khan Naseem,Shaman Heena,Ahmed Shubbir,Kumar Rajesh,Deshpande Suprit,Subramani Chandru,Wadhwa Nitya,Gupta Nimesh,Pandey Anil K,Bhattacharya Jayanta,Agrawal Anurag,Vrati Sudhanshu,Bhatnagar Shinjini,Garg Pramod Kumar

Funder

Department of Biotechnology Ministry of Science and Technology

CSIR

Fondation Botnar

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference27 articles.

1. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera;Supasa;Cell,2021

2. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination;Wall;Lancet,2021

3. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7;Wang;Nature,2021